Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25696915 | 0.75 | NPC1 (0.43) | RAB9AKDM4ESMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL12086507 | 0.74 | ALDH1A1 (0.46) | RAB9AKDM4ESMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL23682636 | 0.74 | NPC1 (0.42) | RAB9AKDM4ESMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL23815538 | 0.72 | NPC1 (0.40) | RAB9AKDM4ESMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL13994276 | 0.72 | KDM4E (0.58) | RAB9AKDM4ESMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL6085397 | 0.71 | KDM4E (0.42) | RAB9AKDM4ESMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL27870455 | 0.71 | KDM4E (0.46) | KDM4EALDH1A1MAPT | |
| SCHEMBL28946507 | 0.71 | APP (0.46) | KDM4EALDH1A1GAAMAPTEGFR | |
| SCHEMBL30594656 | 0.69 | ALDH1A1 (0.52) | RAB9AKDM4ESMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL27365633 | 0.69 | ALDH1A1 (0.52) | RAB9AKDM4ESMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | RAB9A 3364/4885KDM4E 2182/4885SMN1; SMN2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.